Management of Turner's syndrome in adult life: case-series and systematic review.
OBJECTIVE
To assess the symptoms and outcomes of clinical management in adult patients with Turner's Syndrome.


METHODS
Retrospective case-series and systematic review of the literature.


METHODS
Gynaecological Endocrinology Unit in a teaching hospital.


METHODS
Patients followed in the Gynaecological Endocrinology Unit.


METHODS
Review of medical records and a computer search via several databases to identify journals relevant to the subject were performed.


METHODS
Final height, weight, previous treatments with growth hormone, cardiac or renal malformations, metabolic profile, and additional treatment for osteoporosis.


RESULTS
Thirty-one patients were analysed. Differences in final height were found between groups with monosomy and other karyotypes. Four patients bore congenital cardiac malformations, and six, renal congenital malformations. Nine patients had a previous diagnosis of hypercholesterolemia. The most abnormal hepatic parameter was GGT, with fifteen patients having values over the normality limit. Ten patients were receiving treatment for osteopenia or osteoporosis.


CONCLUSIONS
This case-series provides recommendations for the management of adult patients with Turner's syndrome and insight into the different medical complaints of this syndrome. A link between karyotypes and clinical features suggests a novel hypothesis to explain the different phenotypes and clinical abnormalities of these patients.
Gynaecologic Endocrinology Unit, Clinic Institute of Gynaecology, Obstetrics and Neonatology-Hospital Clínic, Faculty of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain.
Cristina
C
Ros
Camil
C
Castelo-Branco
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012189:Retrospective Studies; D014424:Turner Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics
D050071:Bone Density Conservation Agents; D019382:Human Growth Hormone